摘要
目的探讨EZH2(enhancer of zeste homolog 2,EZH2)基因在肾透明细胞癌中的表达及其临床意义。方法采用免疫组织化学法分别检测正常肾脏组织(8例)及肾透明细胞癌标本(58例)中EZH2蛋白的表达。结果正常肾脏组织与肾透明细胞癌标本EZH2蛋白表达率分别为12.5%(1/8)、74.1%(43/58)(P<0.05)。肾透明细胞癌标本中,局部进展性肾癌(Ⅲ)与转移性肾癌(Ⅳ)EZH2蛋白表达明显高于局限性肾癌(Ⅰ+Ⅱ)(P<0.05);高分化肾癌、中分化肾癌及低分化肾癌EZH2蛋白表达不具有显著性差异。结论EZH2在肾透明细胞癌明显高表达,提示其与肾透明细胞癌的发生、发展密切相关,对于肾透明细胞癌的早期诊断及判断预后可能有重要的意义。
Objective To explore the expression of EZH2 in clear cell carcinoma and its significance. Methods EZH2 protein expression was assessed by immunohistochemical method in tissue specimens of normal nephridium and clear cell carcinoma. Results The rate of EZH2 protein expression was 12.5% and 74.1% （P〈0. 05） in the normal nephridium group and the clear cell carcinoma group, respectively. EZH2 protein expression was increased in localized advanced renal cell carcinoma （ Ⅲ ） and metastatic renal cell carcinoma （ Ⅳ ） compared with localized renal cell carcinoma （Ⅰ ＋ Ⅱ ） （P 〈 0. 05）. There were no significant differences in EZH2 protein expression levels among well-differentiated renal cell carcinoma, moderately differentiated renal cell carcinoma and poorly differentiated renal cell carcinoma. Gonclusion Our data show a significant increase in EZH2 expression in clear cell carcinoma compared with normal nephridial tissue, which suggests that increased EZH2 overexpression correlates with oncogenesis and development of clear cell carcinoma. EZH2 may play an important role in early diagnosis and prognosis for clear cell carcinoma.
出处
《西安交通大学学报（医学版）》
CAS
CSCD
北大核心
2009年第2期218-220,共3页
Journal of Xi’an Jiaotong University（Medical Sciences）
